Vaxxas announced Monday that it raised $20 million in a Series B round, which will be used to advance a series of clinical programs and to develop a pipeline of new vaccine products using the company's needle-free Nanopatch platform.
Biotech upstart Vaxxas raised $20 million in the first close of its B round, cash that'll help the biotech develop a needle-free technology for vaccinations.
Australian nanopatch developer Vaxxas signed on with the World Health Organization this week in an effort to co-opt the company's patch for use with the polio vaccine. The WHO will help fund the research and move it through preclinical and clinical studies as the organization seeks to make polio a thing of the past.
Drug giant Merck ($MRK) will team up with Australia's Vaxxas to research the startup's drug-delivery patch that targets vaccine to immunological cells just below the skin's surface.
The deal provides Vaxxas with a major pharma collaborator as it relocates business operations from Australia to Cambridge, MA, where new CEO David Hoey hopes to find additional partners, he told FierceBiotech in an interview.
Australia's Vaxxas has garnered about $16.46 million in venture capital financing to support development of its Nanopatch delivery technology, which the company says could drastically change how